Compare AMPH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | PHAT |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 971.8M | 894.0M |
| IPO Year | 2005 | 2019 |
| Metric | AMPH | PHAT |
|---|---|---|
| Price | $19.03 | $10.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $28.38 | $19.83 |
| AVG Volume (30 Days) | 614.5K | ★ 996.2K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $719,887,000.00 | $175,110,000.00 |
| Revenue This Year | $6.90 | $93.04 |
| Revenue Next Year | $4.64 | $58.91 |
| P/E Ratio | $139.07 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $16.65 | $7.61 |
| 52 Week High | $31.26 | $18.31 |
| Indicator | AMPH | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 51.98 |
| Support Level | $18.92 | $10.02 |
| Resistance Level | $19.81 | $12.99 |
| Average True Range (ATR) | 0.76 | 0.65 |
| MACD | 0.08 | 0.17 |
| Stochastic Oscillator | 41.78 | 81.49 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.